|Bid||7.15 x 1300|
|Ask||7.74 x 1100|
|Day's Range||7.34 - 7.63|
|52 Week Range||6.56 - 29.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
-Initiated enrollment in dose escalation cohorts of Phase 1/ 2 ICONIC trial of JTX-2011, in combination with ipilimumab and in combination with pembrolizumab-. -Presented preliminary efficacy data for ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Jounce Therapeutics, Inc. (NASDAQ: JNCE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:00 AM Eastern ...
CAMBRIDGE, Mass., Aug. 02, 2018-- Jounce Therapeutics, Inc., a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced ...
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Core-Mark ...
NEW YORK, NY / ACCESSWIRE / June 5, 2018 / While shares of Deciphera skyrocketed yesterday and hit a new high on positive data results, shares of Jounce Therapeutics saw the opposite result on its own ...
Jounce Therapeutics, Inc. (JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today presented preliminary data from its ongoing Phase 1/2 ICONIC trial, an adaptive design, open-label trial evaluating JTX-2011 alone and in combination with nivolumab in patients with advanced solid tumors. Safety and preliminary clinical activity data from all evaluable patients across multiple tumor types will be presented in an oral presentation today, Saturday, June 2, 2018 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. “We are encouraged by the early signal of clinical activity in heavily pre-treated patients, accompanied by an ICOS pharmacodynamic biomarker.
NEW YORK, NY / ACCESSWIRE / May 18, 2018 / Both Loxo Oncology and Jounce Therapeutics shares went in different directions after traders absorbed abstract reveals from each company. Shares of Loxo soared ...